1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired 1,326,100 shares of SiBone, valued at approximately $18.6 million, representing 3.12% of the company's stock.
• Insider trades include CFO Anshul Maheshwari selling 5,005 shares, reducing his ownership by 2.25%, while Director Jeffrey W. Dunn sold 3,377 shares, decreasing his ownership by 16.29%.
• SiBone's stock price recently opened at $15.49, with a twelve-month range of $11.70 to $20.05, and is currently rated as a "Buy" by several firms with an average target price of $23.67.

Nuveen LLC acquired a new stake in SiBone (NASDAQ:SIBN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,326,100 shares of the company's stock, valued at approximately $18,605,000. Nuveen LLC owned approximately 3.12% of SiBone at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone in the first quarter valued at about $34,000. Virtus Fund Advisers LLC bought a new stake in shares of SiBone in the fourth quarter valued at about $40,000. GAMMA Investing LLC raised its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after acquiring an additional 3,867 shares in the last quarter. Johnson Investment Counsel Inc. bought a new stake in shares of SiBone in the first quarter valued at about $148,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of SiBone in the first quarter valued at about $162,000. 98.11% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Laura Francis sold 11,343 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.60, for a total value of $176,950.80. Following the transaction, the chief executive officer owned 419,704 shares in the company, valued at approximately $6,547,382.40. This represents a 2.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John Gordon Freund sold 12,132 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the transaction, the director owned 91,767 shares in the company, valued at approximately $1,467,354.33. This trade represents a 11.68% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,967 shares of company stock valued at $829,469. 3.90% of the stock is owned by company insiders.

SiBone Stock Down 2.1%

Shares of SIBN traded down $0.34 during mid-day trading on Monday, hitting $16.05. 243,377 shares of the company traded hands, compared to its average volume of 515,563. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $692.40 million, a PE ratio of -28.66 and a beta of 0.91. The business has a 50 day moving average of $17.03 and a 200 day moving average of $16.51.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million for the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Equities research analysts anticipate that SiBone will post -0.78 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on SIBN. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of SiBone in a report on Tuesday, May 6th. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Truist Financial boosted their target price on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, SiBone currently has a consensus rating of "Buy" and a consensus target price of $23.67.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.